6 results about "Aggrecan" patented technology

The present invention provides a use of a ugonin compound for the treatment of joint-related diseases by enhancing chondrogenesis. More specifically, the chondrogenesis is mediated by the ugonin compound’s ability to promote the increase of aggrecan and type II collagen, which is achieved through the inhibition of miR-3074-5p and the activation of the MAPK signaling pathway.

The invention discloses a CD24 positive nucleus pulposus progenitor cell for inhibiting nucleus pulposus cell ferroptosis, a pharmaceutical composition and application. The invention firstly protects an isolated CD24 + NPPCs population and a pharmaceutical composition thereof. The invention protects the application of the cell population and the pharmaceutical composition in preparation of drugs for inhibiting nucleus pulposus cell ferroptosis and / or improving intervertebral disc degeneration microenvironment. The nucleus pulposus progenitor cell subgroup is enriched and obtained by taking CD24 as a marker. Experiments prove that the cell population can play a role through a multiple synergistic mechanism: on one hand, the ferroptosis of nucleus pulposus cells is effectively inhibited by up-regulating proteins such as GPX4 and SLC7A11 and reducing lipid peroxidation; on the other hand, by reducing the level of proinflammatory factors such as TNF-alpha and promoting synthesis of extracellular matrixes such as Aggrecan and COL2A1, the healthy intervertebral disc microenvironment is remodeled, and tissue regeneration is promoted.

A processed human umbilical cord composition for treating Peyronie's disease by intracorporeal injection of an effective amount into a subject in need thereof, the composition comprising an aqueous human umbilical cord filtrate containing endogenous hyaluronic acid (HA) and / or hyaluronan, fibronectin, insulin growth factor binding protein-1 (IGFBP-1), sulfated glycosaminoglycans (sGAGs), exosomes, interleukin-1 receptor antagonist (IL-1ra), hepatocyte growth factor (HGF), transthyretin, tissue inhibitor of metalloproteinase 1 (TIMP-1), aggrecan, or a combination thereof, in an amount effective to reduce the size of Peyronie's disease plaques.

The invention discloses injectable bioactive matrix hydrogel with an anti-angiogenesis and anti-neurogenesis microenvironment and application of the injectable bioactive matrix hydrogel. The injectable bioactive matrix hydrogel is prepared from bevacizumab, a concentrated growth factor and methacrylic acid chondroitin sulfate. The hydrogel prepared by the invention not only shows excellent injectability and biocompatibility, but also can inhibit pathological vascularization and neurogenesis, polarize macrophages to promote regeneration of M2 phenotype so as to relieve inflammation, and directly enhance deposition of cartilage specific ECM components (such as type II collagen and aggregation proteoglycan). By utilizing the coordinated multi-mechanism strategy, the comprehensive structure and function repair of the degenerated intervertebral disc is realized.

The present invention relates to a composition for the prevention or treatment of rheumatoid arthritis, comprising, as an active ingredient, a supercritical extract of Acanthopanax sessiliflorus Harms. In the present invention, it was confirmed that, upon administration of the supercritical extract of Acanthopanax sessiliflorus Harms to a rheumatoid arthritis animal model, pain induced by rheumatoid arthritis was reduced and cartilage damage was suppressed. Also, a decrease in the infiltration of immune cells in cartilage tissue was confirmed, and it was confirmed that the expression of Col2a1, Sox9, and Aggrecan, which are cartilage anabolic factors whose expression is reduced by inflammatory cytokines and inflammatory factors, was increased, and the expression of Mmp3, Mmp10, Mmp13, and Adamts5, which are cartilage catabolic factors, was reduced. It was also confirmed that pimaric acid and kaurenoic acid, which are useful components of the supercritical extract of Acanthopanax sessiliflorus Harms, protected chondrocytes and suppressed the differentiation of Th17 cells, which are pathogenic cells in rheumatoid arthritis.